Skip to content

Study · Non-randomized trial · n = 14 · 1987

3 results

Blind evaluation of the effect of octreotide (SMS 201-995), a somatostatin analogue, on small-bowel fistula output.

Nubiola-Calonge P, Badía JM, Sancho J, Gil MJ, Segura M, Sitges-Serra A

Lancet (London, England)1 Sept 1987Cited by 50 (Europe PMC)

PMID2887951 (opens in a new tab)DOI10.1016/s0140-6736(87)92452-4 (opens in a new tab)PepBankPUB-02887951
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In postoperative fistula patients, 11 fistulae closed spontaneously after continuous octreotide, in an average of 4.5 days.

    In plain wordsIn postoperative fistula patients, 11 fistulae closed after continuous octreotide, in an average of 4.5 days.

    Peptide
    Octreotide
    Outcome
    Not applicableSpontaneous fistula closure
    Study

    n = 14

    Outcome group
    Wound healing · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Patients with spontaneous fistula closure
    11 patients
    after continuous octreotide; 14 patients treated
    Time to fistula closure
    4.5 days
    average, after continuous octreotide

    Source sentences

    Summary
    In 11 patients fistulae closed spontaneously in an average of 4.5 days after continous treatment with octreotide.
    2 context sentences
    Summary · context
    after which all patients were treated with octreotide until the fistula closed or reoperation was deemed necessary.
    Summary · context
    In a blind crossover trial for 4 days, after at least 7 days on conventional treatment, 14 patients with postoperative small-bowel fistula were randomised to 2 days on a somatostatin analogue, octreotide (SMS 201-995), followed by 2 days on placebo (group 1) or vice versa (group 2)
  2. 02HumanNon-randomized trialEfficacy outcome

    In group 2 postoperative fistula patients, octreotide reduced output from 698 ml per 24 h pretreatment to 246 mg per 24 h after 2 days.

    In plain wordsIn postoperative fistula patients, output decreased after two days of octreotide compared with pretreatment.

    Peptide
    Octreotide
    Outcome
    DecreaseGroup 2 fistula output after octreotide
    Study

    n: not reported in source

    Comparator
    Pretreatment
    Outcome group
    Wound healing · Gastrointestinal
    Studied dose
    Dose not stated · 2 daysAs given in this study (human).

    Measurements

    Mean fistula output
    698 ml per 24 h
    group 2, pretreatment
    Mean fistula output
    246 mg per 24 h
    group 2, after 2 days on octreotide; unit as written in the abstract

    Source sentences

    Summary
    In group 2 mean fistula output was reduced from 698 ml per 24 h pretreatment to 246 mg per 24 h after 2 days on octreotide
    1 context sentence
    Summary · context
    In a blind crossover trial for 4 days, after at least 7 days on conventional treatment, 14 patients with postoperative small-bowel fistula were randomised to 2 days on a somatostatin analogue, octreotide (SMS 201-995), followed by 2 days on placebo (group 1) or vice versa (group 2)
  3. 03HumanNon-randomized trialEfficacy outcome

    In postoperative fistula patients, output increased from 228 to 497 ml per 24 h when placebo interrupted octreotide treatment.

    In plain wordsIn postoperative fistula patients, output was lower during octreotide treatment than after placebo replaced it.

    Peptide
    Octreotide
    Outcome
    DecreaseFistula output with withdrawal
    Study

    n: not reported in source

    Comparator
    Placebo after octreotide withdrawal
    Outcome group
    Wound healing · Gastrointestinal
    Studied dose
    Dose not stated · 2 daysAs given in this study (human).

    Measurements

    Fistula output
    228 ml per 24 h
    before placebo interruption, on octreotide
    Fistula output
    497 ml per 24 h
    when octreotide was interrupted by placebo

    Source sentences

    Summary
    output increased from 228 ml per 24 h to 497 ml per 24 h when treatment with octreotide was interrupted by placebo.
    1 context sentence
    Summary · context
    In a blind crossover trial for 4 days, after at least 7 days on conventional treatment, 14 patients with postoperative small-bowel fistula were randomised to 2 days on a somatostatin analogue, octreotide (SMS 201-995), followed by 2 days on placebo (group 1) or vice versa (group 2)

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.